Contribute Try STAT+ Today

Back again with another semi-regular column on the Covid-19 pandemic. You can read my first go at this effort here, which was only Tuesday but feels like two weeks ago. I had to double-check the date because days blur together when you work and live in the same place. In this edition: A Bellus Health study is NOT delayed; other studies are; A Pfizer-inspired plea for greater shareholder outreach; and a feel-good story from Agios Pharma.

The coronavirus is seriously disrupting, and in some cases suspending, clinical trials, with significant impacts on drug development. More on this problem for biotech, and what’s being done to fix it, in a moment. First, let’s focus on some good news from one closely followed clinical trial.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.